Monitor blood pressure periodically. Significant bladder outlet obstruction, patients taking antimuscarinic drugs for OAB: risk of urinary retention. Discontinue and treat if angioedema of the ...
A US district court has said that a key patent held by Astellas on its Myrbetriq drug for urinary incontinence is invalid, in a setback to its efforts to defend the blockbuster therapy from ...
Low-cost competition in the US to Astellas’ Myrbetriq for urinary incontinence ... which also covers extended-release formulations of the drug. The Japanese drugmaker suffered a defeat in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results